Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Journal of Biopharmaceutical Statistics
|
March 11, 2011
Analysis of missing mechanism in IVUS imaging clinical trials with missing covariates
Mingxiu Hu, Tianyue Zhou
Pharmaceutical Statistics
|
November 27, 2015
Testing multiple primary endpoints in clinical trials with sample size adaptation
Yi Liu, Mingxiu Hu
The AAPS Journal
|
June 27, 2006
An automated process for building reliable and optimal in vitro/in vivo correlation models based on Monte Carlo simulations
Steven C Sutton, Mingxiu Hu
Contemporary Clinical Trials
|
November 9, 2020
Statistical adaptation to oncology drug development evolution
Mingxiu Hu, Miao Yang, Yi Liu
Journal of Biopharmaceutical Statistics
|
July 11, 2019
<i>Z</i><sub>max</sub> test for delayed effect in immuno-oncology clinical trials
Miao Yang, Zhaowei Hua, Lan Xue, et al.
Clinical Trials (London, England)
|
September 13, 2007
Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes
Mingxiu Hu, Joseph C Cappelleri, K K Gordon Lan
American Journal of Clinical Pathology
|
June 6, 2002
Probability-based construction of reference ranges for ratios of log-gaussian analytes: an example from automated leukocyte counts
Donald C Trost, Mingxiu Hu, Allison G Brailey, et al.
Contemporary Clinical Trials
|
July 9, 2008
Daily process methodology for measuring earlier antidepressant response
William R Lenderking, Mingxiu Hu, Howard Tennen, et al.
The American Journal of Cardiology
|
January 21, 2011
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region
Jim Gilbert, Julie Lekstrom-Himes, Debra Donaldson, et al.
Lancet (London, England)
|
March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Anwen Xiong, Lei Wang, Jianhua Chen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Journal of Biopharmaceutical Statistics
|
March 11, 2011
Analysis of missing mechanism in IVUS imaging clinical trials with missing covariates
Mingxiu Hu, Tianyue Zhou
Pharmaceutical Statistics
|
November 27, 2015
Testing multiple primary endpoints in clinical trials with sample size adaptation
Yi Liu, Mingxiu Hu
The AAPS Journal
|
June 27, 2006
An automated process for building reliable and optimal in vitro/in vivo correlation models based on Monte Carlo simulations
Steven C Sutton, Mingxiu Hu
Contemporary Clinical Trials
|
November 9, 2020
Statistical adaptation to oncology drug development evolution
Mingxiu Hu, Miao Yang, Yi Liu
Journal of Biopharmaceutical Statistics
|
July 11, 2019
<i>Z</i><sub>max</sub> test for delayed effect in immuno-oncology clinical trials
Miao Yang, Zhaowei Hua, Lan Xue, et al.
Clinical Trials (London, England)
|
September 13, 2007
Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes
Mingxiu Hu, Joseph C Cappelleri, K K Gordon Lan
American Journal of Clinical Pathology
|
June 6, 2002
Probability-based construction of reference ranges for ratios of log-gaussian analytes: an example from automated leukocyte counts
Donald C Trost, Mingxiu Hu, Allison G Brailey, et al.
Contemporary Clinical Trials
|
July 9, 2008
Daily process methodology for measuring earlier antidepressant response
William R Lenderking, Mingxiu Hu, Howard Tennen, et al.
The American Journal of Cardiology
|
January 21, 2011
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region
Jim Gilbert, Julie Lekstrom-Himes, Debra Donaldson, et al.
Lancet (London, England)
|
March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
Anwen Xiong, Lei Wang, Jianhua Chen, et al.
Page
of 2